Cargando…

Treatment of bloodstream infections in ICUs

Bloodstream infections (BSIs) are frequent in ICU and is a prognostic factor of severe sepsis. Community acquired BSIs usually due to susceptible bacteria should be clearly differentiated from healthcare associated BSIs frequently due to resistant hospital strains. Early adequate treatment is key an...

Descripción completa

Detalles Bibliográficos
Autores principales: Timsit, Jean-François, Soubirou, Jean-François, Voiriot, Guillaume, Chemam, Sarah, Neuville, Mathilde, Mourvillier, Bruno, Sonneville, Romain, Mariotte, Eric, Bouadma, Lila, Wolff, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289315/
https://www.ncbi.nlm.nih.gov/pubmed/25431091
http://dx.doi.org/10.1186/1471-2334-14-489
_version_ 1782352091395653632
author Timsit, Jean-François
Soubirou, Jean-François
Voiriot, Guillaume
Chemam, Sarah
Neuville, Mathilde
Mourvillier, Bruno
Sonneville, Romain
Mariotte, Eric
Bouadma, Lila
Wolff, Michel
author_facet Timsit, Jean-François
Soubirou, Jean-François
Voiriot, Guillaume
Chemam, Sarah
Neuville, Mathilde
Mourvillier, Bruno
Sonneville, Romain
Mariotte, Eric
Bouadma, Lila
Wolff, Michel
author_sort Timsit, Jean-François
collection PubMed
description Bloodstream infections (BSIs) are frequent in ICU and is a prognostic factor of severe sepsis. Community acquired BSIs usually due to susceptible bacteria should be clearly differentiated from healthcare associated BSIs frequently due to resistant hospital strains. Early adequate treatment is key and should use guidelines and direct examination of samples performed from the infectious source. Previous antibiotic therapy knowledge, history of multi-drug resistant organism (MDRO) carriage are other major determinants of first choice antimicrobials in heathcare-associated and nosocomial BSIs. Initial antimicrobial dose should be adapted to pharmacokinetic knowledge. In general, a high dose is recommended at the beginning of treatment. If MDRO is suspected combination antibiotic therapy is mandatory because it increase the spectrum of treatment. Most of time, combination should be pursued no more than 2 to 5 days. Given the negative impact of useless antimicrobials, maximal effort should be done to decrease the antibiotic selection pressure. De-escalation from a broad spectrum to a narrow spectrum antimicrobial decreases the antibiotic selection pressure without negative impact on mortality. Duration of therapy should be shortened as often as possible especially when organism is susceptible, when the infection source has been totally controlled. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-489) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4289315
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42893152015-01-11 Treatment of bloodstream infections in ICUs Timsit, Jean-François Soubirou, Jean-François Voiriot, Guillaume Chemam, Sarah Neuville, Mathilde Mourvillier, Bruno Sonneville, Romain Mariotte, Eric Bouadma, Lila Wolff, Michel BMC Infect Dis Review Bloodstream infections (BSIs) are frequent in ICU and is a prognostic factor of severe sepsis. Community acquired BSIs usually due to susceptible bacteria should be clearly differentiated from healthcare associated BSIs frequently due to resistant hospital strains. Early adequate treatment is key and should use guidelines and direct examination of samples performed from the infectious source. Previous antibiotic therapy knowledge, history of multi-drug resistant organism (MDRO) carriage are other major determinants of first choice antimicrobials in heathcare-associated and nosocomial BSIs. Initial antimicrobial dose should be adapted to pharmacokinetic knowledge. In general, a high dose is recommended at the beginning of treatment. If MDRO is suspected combination antibiotic therapy is mandatory because it increase the spectrum of treatment. Most of time, combination should be pursued no more than 2 to 5 days. Given the negative impact of useless antimicrobials, maximal effort should be done to decrease the antibiotic selection pressure. De-escalation from a broad spectrum to a narrow spectrum antimicrobial decreases the antibiotic selection pressure without negative impact on mortality. Duration of therapy should be shortened as often as possible especially when organism is susceptible, when the infection source has been totally controlled. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-489) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-28 /pmc/articles/PMC4289315/ /pubmed/25431091 http://dx.doi.org/10.1186/1471-2334-14-489 Text en © Timsit et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Timsit, Jean-François
Soubirou, Jean-François
Voiriot, Guillaume
Chemam, Sarah
Neuville, Mathilde
Mourvillier, Bruno
Sonneville, Romain
Mariotte, Eric
Bouadma, Lila
Wolff, Michel
Treatment of bloodstream infections in ICUs
title Treatment of bloodstream infections in ICUs
title_full Treatment of bloodstream infections in ICUs
title_fullStr Treatment of bloodstream infections in ICUs
title_full_unstemmed Treatment of bloodstream infections in ICUs
title_short Treatment of bloodstream infections in ICUs
title_sort treatment of bloodstream infections in icus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289315/
https://www.ncbi.nlm.nih.gov/pubmed/25431091
http://dx.doi.org/10.1186/1471-2334-14-489
work_keys_str_mv AT timsitjeanfrancois treatmentofbloodstreaminfectionsinicus
AT soubiroujeanfrancois treatmentofbloodstreaminfectionsinicus
AT voiriotguillaume treatmentofbloodstreaminfectionsinicus
AT chemamsarah treatmentofbloodstreaminfectionsinicus
AT neuvillemathilde treatmentofbloodstreaminfectionsinicus
AT mourvillierbruno treatmentofbloodstreaminfectionsinicus
AT sonnevilleromain treatmentofbloodstreaminfectionsinicus
AT mariotteeric treatmentofbloodstreaminfectionsinicus
AT bouadmalila treatmentofbloodstreaminfectionsinicus
AT wolffmichel treatmentofbloodstreaminfectionsinicus